全氟己基辛烷(Perfluorohexyloctane) - 药物靶点：Lipid_在研适应症：干眼症，干眼综合征_专利_临床

A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months

开始日期2024-07-31

申办/合作机构

Bausch & Lomb, Inc.

NCT06346340

/ Completed临床4期

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy

开始日期2024-04-30

申办/合作机构

Bausch & Lomb, Inc.

NCT06309953

/ Completed临床4期

An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

开始日期2024-02-28

申办/合作机构

Bausch & Lomb, Inc.

100 项与全氟己基辛烷相关的临床结果

登录后查看更多信息

100 项与全氟己基辛烷相关的转化医学

登录后查看更多信息

100 项与全氟己基辛烷相关的专利（医药）

登录后查看更多信息

128

项与全氟己基辛烷相关的文献（医药）

2025-04-01·Ophthalmology and Therapy

Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study

Article

作者: Gupta, Preeya K ; Vittitow, Jason L ; Razeen, Moataz ; Chester, Thomas M ; Kannarr, Shane R ; Bacharach, Jason ; White, Darrell E ; Lang, Jacob ; Ziemanski, Jillian F ; Cavet, Megan E ; Verachtert, Anthony

INTRODUCTION:

Perfluorohexyloctane ophthalmic solution (PFHO) is indicated for the treatment of signs and symptoms of dry eye disease (DED) and targets excessive tear evaporation. This study evaluated patient-reported outcomes early in treatment with PFHO.

METHODS:

This prospective, multicenter, open-label, phase 4 study enrolled adults with a history of DED for ≥ 6 months. PFHO was instilled in both eyes four times daily for 14 days. Patients completed early outcome surveys during four clinic visits (day 1 [pretreatment; 5 and 60 min post-PFHO instillation] and days 3, 7, and 14). Symptom severity, symptom frequency, and treatment satisfaction were rated on visual analog scales (range 0-100). The primary endpoint was mean change from baseline in overall DED symptom severity at day 7. Secondary endpoints included change in severity of individual DED symptoms (eye dryness, blurred vision, eye irritation, light sensitivity, eye tiredness, burning/stinging, eye itching, eye pain); change in frequency (measured as percentage of time experienced) of the most bothersome symptom, awareness of dry eye symptoms, and fluctuation in quality of vision; and treatment satisfaction.

RESULTS:

Ninety-nine patients enrolled (85.9% female; age range 35-81 years). The primary endpoint was met: mean (SD) overall symptom severity decreased significantly from 72.1 (17.0) at baseline to 27.8 (22.3) at day 7 (mean change, - 44.5; P < 0.0001). Mean (SD) percentage of time experiencing the most bothersome symptom decreased from 77.9% at baseline to 34.7% at day 14 (P < 0.0001). Significant reductions in severity and frequency also were observed for all symptoms at all postbaseline assessments (P < 0.0001). Median ratings of treatment satisfaction were 83.0 at day 3, 86.0 at day 7, and 90.0 at day 14.

CONCLUSION:

Early in the course of treatment with PFHO, patients with DED experienced significant reductions in dry eye symptom frequency and severity. Treatment satisfaction with PFHO was high.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier NCT06309953.

2025-03-01·CORNEA

In Vitro and In Vivo Visualization of Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Using Infrared Emissivity

Article

作者: Vittitow, Jason ; Cavet, Megan ; Borchman, Douglas ; Ahmed, Simra ; Millar, Thomas James

Purpose::

To visualize the behavior of perfluorohexyloctane (PFHO), an eye drop to treat dry eye disease (DED), on the surface of saline in vitro and on the human ocular surface using infrared emissivity.

Methods::

Emissivity videos were used to measure the spreading and disappearance rates of PFHO on saline (with and without mucin for spreading rate) and layered over a 125 nm film of meibum on the surface of saline using a TearView camera. Ocular surface emissivity was videoed in a volunteer without DED before and after instillation of 1 drop of PFHO. Videos were exported and converted to still photographs, and grayscale levels measured.

Results::

PFHO formed a layer over saline that spread at a mean (SD) rate of 0.89 (0.5) cm2/s and disappeared at 0.0760 (0.0055) μL/min, consistent with reported rates of evaporation for PFHO. Mucin in the subphase did not alter spreading rate (P > 0.2). In vitro, a single drop of PFHO spread over the top of a 125-nm thick film of meibum remaining for 3.3 hours. In the volunteer, an increase in emissivity was detected on the ocular surface for ≥5 hours.

Conclusions::

PFHO quickly spread to form a layer over the surface of saline or meibum in vitro and was detected on the ocular surface in vivo for ≥5 hours after topical administration. This supports findings that PFHO forms a long-lasting barrier to evaporation at the air–liquid interface of the tear film and thus reduces signs and symptoms of DED.

2025-02-05·Cureus Journal of Medical Science

Recalcitrant Dry Eye Disease in a 31-Year-Old Female: Favorable Outcomes Following Complete Ocular Lavage Facilitated by an Irrigating Eyelid Retractor

Article

作者: Maiti, Sathi ; Kondapalli, Srinivas Sai A ; Periman, Laura M

This report explores the management of an otherwise healthy 31-year-old Caucasian female with chronic, refractory dry eye disease (DED) unresponsive to extensive conventional therapies. The initial treatment included artificial tears, cyclosporine, hypochlorous acid spray, and thermal eyelid pulsation, which provided limited relief. Progressive therapeutic interventions, such as intense pulsed light, varenicline nasal spray, perfluorohexyloctane drops, platelet-rich plasma, and topical antibiotics, resulted in only modest improvement over 15 months. Persistent symptoms and corneal staining prompted the implementation of a novel treatment: high-pressure ocular surface lavage using an irrigating eyelid retractor (Rinsada®) with preservative-free saline. Post-lavage, the patient experienced immediate and significant symptomatic relief, with marked improvement in corneal staining noted on slit lamp examination. Continued improvement was observed over two weeks following the procedure. This report underscores the potential of high-pressure saline irrigation for addressing inflammatory mediators and biofilm on the ocular surface. The irrigating eyelid retractor enabled precise and effective lavage of the palpebral conjunctiva and fornices, reducing the inflammatory load and resetting the ocular surface. This technique represents a promising adjunctive therapy for recalcitrant DED, offering rapid symptom relief and improved clinical outcomes. Further studies are warranted to validate these findings and optimize patient care.

161

项与全氟己基辛烷相关的新闻（医药）

2025-07-03

·药筛

7个新药、1个首仿批文卡点国谈，乐明氟比洛芬凝胶贴膏获批

今天，NMPA发了多个新批文，多个品种值得关注。首先，就是昨天药监局新闻公布的4款新药品种批文，获批是6月30日，正好赶上新国谈的批文截止获批日期。时间刚刚好！注射用盐酸伊吡诺司他广州必贝特医药股份有限公司，1类创新药注射用盐酸伊吡诺司他（商品名：贝特琳），该药品单药适用于既往接受过至少两线系统性治疗的复发或难治性弥漫性大B细胞淋巴瘤成人患者。酒石酸泰瑞西利胶囊贝达药业股份有限公司，1类创新药酒石酸泰瑞西利胶囊（商品名：康美纳），该药品联合氟维司群，适用于既往接受内分泌治疗后进展的激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性的局部晚期或转移性成年乳腺癌患者。注射用伏欣奇拜单抗长春金赛药业有限责任公司，注射用伏欣奇拜单抗（商品名：金蓓欣）上市，适用于对非甾体类抗炎药和/或秋水仙碱禁忌、不耐受或缺乏疗效的，以及不适合反复使用类固醇激素的成人痛风性关节炎急性发作。注射用苏维西塔单抗江苏先声生物制药有限公司，注射用苏维西塔单抗（商品名：恩泽舒）上市，适应症为：苏维西塔单抗联合紫杉醇、多柔比星脂质体或拓扑替康用于铂耐药后接受过不超过1种系统治疗的成人复发性卵巢癌、输卵管癌或原发性腹膜癌的治疗。另外，还有3个品种，也是赶在6月30日前获批，分别是：恒瑞的全氟己基辛烷滴眼液；四川科瑞德的盐酸替扎尼定口服溶液；正大天晴的注射用重组人凝血因子Ⅶa N01；仿制药方面乐明药业的氟比洛芬凝胶贴膏获批，国内第4家，也是来自不易啊。后面还有多个受理号在审中。齐鲁的注射用奥氮平首仿获批，也是独家申报，正好也赶上国谈。快速筛选药品，就用摩熵药筛小程序

上市批准

2025-07-03

·恒瑞医药

恒瑞医药海外引进的全氟己基辛烷滴眼液（恒沁®）获批，干眼治疗迎来新选择！

近日，恒瑞医药子公司成都盛迪医药有限公司收到国家药品监督管理局的通知，批准公司全氟己基辛烷滴眼液(恒沁®)上市。该产品是目前全球唯一一款用于治疗睑板腺功能障碍（MGD）相关干眼的药品，将为我国此类患者提供全新的药物治疗选择。据《中国干眼临床诊疗指南（2023年）》1，我国干眼的发病率为21%-30%。一项临床研究结果显示2,3，69%-86%的干眼人群患有MGD。这表明在治疗干眼病时，针对睑板腺功能障碍的治疗显得尤为重要。根据《中国睑板腺功能障碍专家共识：诊断和治疗（2023年）》4，目前MGD的基础治疗为物理治疗，药物治疗现有的五种类别尚无一款直接针对MGD治疗的药物。因此，目前临床亟需一款有针对性、疗效好、安全性高的治疗MGD相关干眼病的药物。2019年，恒瑞医药从Novaliq公司引进全氟己基辛烷滴眼液，并拥有该产品在中国的独家权利。全氟己基辛烷滴眼液是基于全球首个无水药物递送技术平台EyeSol®研发的药物，由单一组分全氟己基辛烷（F6H8）组成，无水，不含油脂、表面活性剂和防腐剂等赋形剂5,6。它拥有极低的表面张力5，可迅速扩散至眼表面7，同时可以改善脂质层等级，抑制泪液蒸发，促进角膜上皮修复8,9。此外，全氟己基辛烷滴眼液还能补充非极性油脂成分，增加泪膜厚度，疏通睑板腺，改善睑脂分泌8,9。鉴于其独特的创新性和临床急需性，恒瑞医药立足中国临床开发要求和实践，按照创新药技术要求在国内开展完整的关键临床研究，并于2023年2月申报上市获国家药监局受理。本次该产品在境内获批上市，关键注册研究是基于一项多中心、随机、双盲、对照的Ⅲ期临床研究（NCT05515471）10。研究结果表明，与安慰剂对比，全氟己基辛烷滴眼液可以治疗睑板腺功能障碍相关干眼病，显著改善患者的干眼病症状和体征。同时，全氟己基辛烷滴眼液安全可靠，局部耐受性好。在国际市场，全氟己基辛烷滴眼液于2013年通过欧盟CE MARK认证，按医疗器械在欧洲上市。2023年5月，Novaliq公司全氟己基辛烷滴眼液（此前称NOV03）按505b（1）新分子实体（New Molecular Entity）路径获FDA批准上市，用于治疗干眼的体征和症状，为一种直接针对泪液蒸发的干眼创新疗法。作为创新型国际化制药企业，恒瑞医药多年来持续围绕临床急需进行创新研发，累计研发投入达460亿元，已在国内获批上市23款1类创新药和4款2类新药，另有90多个自主创新产品正在临床开发，约400项临床试验在国内外开展。除了深耕传统优势的肿瘤领域，公司还在代谢和心血管疾病、免疫和呼吸系统疾病以及神经科学等多个领域进行广泛布局。聚焦到眼科疾病，公司已有多款滴眼液在研或上市。在近视领域，公司防控儿童近视进展的HR19034滴眼液上市申请已获国家药监局受理；在干眼病领域，除全氟己基辛烷滴眼液外，SHR8028滴眼液(环孢素滴眼液（IV）)上市申请也已获得受理。未来，恒瑞医药将继续坚持“以患者为中心”的理念，争分夺秒推进创新药研发，努力研制出更多的新药好药，服务健康中国，惠及全球患者。参考文献:1.中国医师协会眼科医师分会眼表与干眼学组. 中国干眼临床诊疗指南. 北京：科学技术文献出版社，2023.P26-28.2.Jie Y, Xu L, Wu YY, Jonas JB. Prevalence of dry eye among adult Chinese in the Beijing Eye Study. Eye (Lond). 2009 Mar;23:(3):688–693. doi: 10.1038/sj.eye.6703101.3.Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012 May;31(5):472-8. doi: 10.1097/ICO.0b013e318225415a.4.亚洲干眼协会中国分会, 海峡两岸医药卫生交流协会眼科学专业委员会眼表与泪液病学组, 中国医师协会眼科医师分会眼表与干眼学组. 中国睑板腺功能障碍专家共识：诊断和治疗（2023年）J. 中华眼科杂志, 2023, 59(11): 880-887.5.Tsagogiorgas C, Otto M. Semifluorinated Alkanes as New Drug Carriers-An Overview of Potential Medical and Clinical Applications. Pharmaceutics. 2023 Apr 11;15(4):1211. doi: 10.3390/pharmaceutics15041211.6.Sheppard JD, et al. MOJAVE Study Group. NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study. Am J Ophthalmol. 2023 Aug;252:265-274. doi: 10.1016/j.ajo.2023.03.008.7.Agarwal P, et al. Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics. Ocul Surf. 2019 Apr;17(2):241-249. doi: 10.1016/j.jtos.2019.02.010.8.Vittitow J, et al. In Vitro Inhibition of Evaporation with Perfluorohexyloctane, an Eye Drop for Dry Eye Disease. Curr Ther Res Clin Exp. 2023 May 12;98:100704. doi: 10.1016/j.curtheres.2023.100704.9.Steven P, et al. Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease. J Ocul Pharmacol Ther. 2017 Nov;33(9):678-685. doi: 10.1089/jop.2017.0042.10.Tian L, et al. Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial. JAMA Ophthalmol. 2023 Apr 1;141(4):385-392. doi: 10.1001/jamaophthalmol.2023.0270.声明：1.本新闻旨在分享研发注册进展，仅供医疗卫生专业人士参阅，非广告用途。2.恒瑞医药不对任何药品和/或适应症作推荐。3.本新闻中涉及的信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。排版：程梦真责编：李玉莹往期精选| 研发创新 |恒瑞创新药瑞坦宁®获批，用于预防成人高度致吐性化疗引起的急性和迟发性恶心呕吐| 国际化 |恒瑞医药再次与德国默克集团达成合作，推进辅助生殖领域口服GnRH拮抗剂商业化落地恒瑞医药与默沙东就Lp(a)抑制剂HRS-5346签订独家许可协议| 重磅奖项 |捷报！恒瑞医药创新药海曲泊帕乙醇胺片（恒曲®）专利荣获中国专利金奖喜报！恒瑞医药荣获2023年度国家科技进步奖| 社会公益 |“健康中国行·重走长征路”项目启动仪式圆满举行！恒瑞提供公益支持，助力健康中国恒瑞医药集团向中国扶贫基金会捐赠3000万设立“健康帮扶基金”

临床3期上市批准申请上市

2025-07-03

·药圈头条

重磅！礼来「替尔泊肽」新适应症、恒瑞眼科创新药获批上市

刚刚，NMPA发布2025年07月03日药品批准证明文件送达信息，其中多款创新药获批，恒瑞医药的全氟己基辛烷滴眼液获批上市，用于治疗睑板腺功能障碍（MGD）相关干眼病。睑板腺功能障碍（MGD）是一种慢性、弥漫性睑板腺功能异常，可导致泪膜改变、泪膜稳定性降低和眼刺激症状。目前临床治疗方法如物理疗法和人工泪液等因存在局限性，未能达到满意的治疗效果。全氟己基辛烷滴眼液滴眼液是一种无色、透明的滴眼液，由100% 全氟己基辛烷组成，能迅速扩散至整个眼表，并与泪膜的亲脂部分相互作用，稳定泪膜、防止泪液过度蒸发。此外，SHR8058 滴眼液可穿透睑板腺，与腺体相互作用并溶解腺体中的粘性分泌物，从而达到治疗睑板腺功能障碍相关蒸发过强型干眼病的作用。礼来的替尔泊肽注射液获批上市，本次获批适应症为：用于治疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停（OSA）。阻塞性睡眠呼吸暂停是一种常见的睡眠呼吸障碍疾病，睡眠期间上气道完全或部分塌陷，引起呼吸暂停或低通气，伴有血氧饱和度下降和/或微觉醒。患者以夜眠打鼾伴呼吸暂停、日间嗜睡、非恢复性睡眠、疲劳及失眠等为主要临床表现。并且其与交通和职业事故、心血管疾病、神经系统疾病、代谢疾病、癌症、免疫系统疾病、全因死亡风险增加相关。此次替尔泊肽新适应症获批主要基于SURMOUNT-OSA临床3期试验的结果。该试验为期一年，评估了替尔泊肽（10mg或15mg）用于正在接受或不愿接受气道正压通气（positive airway pressure, PAP）的成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停的治疗有效性。对于未使用PAP治疗的成人患者中，替尔泊肽在减少呼吸暂停低通气的效果是安慰剂的5倍，即替尔泊肽可使每小时呼吸暂停低通气次数减少27次，而安慰剂仅减少5次。在使用PAP治疗的成人中，替尔泊肽使每小时呼吸暂停低通气次数减少30次，而安慰剂仅减少6次。经过一年的治疗，在仅使用替尔泊肽的患者中，有43%的成人患者实现了OSA症状完全缓解或无症状的轻度OSA状态，而在同时接受替尔泊肽和PAP治疗的患者中，这一比例为52%；安慰剂组则分别为15%和14%。除了改善OSA症状外，接受替尔泊肽治疗的成人患者平均体重减轻了18.1%，同时接受替尔泊肽和PAP治疗的成人患者平均体重减轻了20.1%；而安慰剂组的成人患者平均体重分别减轻了1.3%和2.3%。替尔泊肽的安全性和耐受性与此前试验中报告的替尔泊肽安全性一致。最常见的不良事件是胃肠道不良事件，程度为轻至中度。此前，替尔泊肽已获NMPA批准适用于：- 在饮食控制和运动基础上，接受二甲双胍和/或磺脲类药物治疗血糖仍控制不佳的成人2型糖尿病患者- 在控制饮食和增加运动基础上，初始体重指数（BMI）符合以下要求的成人的长期体重管理：≥28kg/m2（肥胖），或≥24kg/m2（超重）并伴有至少一种体重相关合并症（例如高血压、血脂异常、高血糖、阻塞性睡眠呼吸暂停、心血管疾病等）

临床3期上市批准临床结果免疫疗法

100 项与全氟己基辛烷相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
干眼症	中国	成都盛迪医药有限公司	2025-06-30
干眼综合征	美国	Bausch & Lomb, Inc.	2023-05-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
睑板腺功能障碍	临床3期	美国	Bausch & Lomb, Inc.	2020-07-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04139798 (GOBI, CTgov)	临床3期	干眼综合征 \| 睑板腺功能障碍	599	NOV03 (NOV03 4 Times Daily (QID))	衊範餘觸夢糧廠齋憲範(醖糧網範齋糧遞壓範鹽) = 廠壓壓願齋淵夢餘壓廠獵鏇獵選廠鹽膚鹹淵積 (憲窪顧繭衊襯膚鬱齋選, 2.6) 更多	-	2024-10-23
				Placebo (Placebo 4 Times Daily (QID))	衊範餘觸夢糧廠齋憲範(醖糧網範齋糧遞壓範鹽) = 糧選鹹壓願顧憲壓獵鹹獵鏇獵選廠鹽膚鹹淵積 (憲窪顧繭衊襯膚鬱齋選, 2.7) 更多
NCT04567329 (MOJAVE Study \| GOBI, CTgov)	临床3期	干眼综合征 \| 睑板腺功能障碍	620	NOV03 (NOV03)	製膚範窪鬱糧網膚獵襯(製遞蓋膚糧鹹繭鹽積鑰) = 鬱餘築窪鏇壓築願積醖夢蓋鬱廠簾餘壓顧膚獵 (艱夢網鑰膚鬱壓夢積遞, 2.8) 更多	-	2024-08-19
				Saline Solution (Saline Solution)	製膚範窪鬱糧網膚獵襯(製遞蓋膚糧鹹繭鹽積鑰) = 衊鏇蓋廠網艱鬱範範觸夢蓋鬱廠簾餘壓顧膚獵 (艱夢網鑰膚鬱壓夢積遞, 2.9) 更多
NCT04140227 (KALAHARI, Pubmed \| Cornea)	临床3期	干眼综合征	208	Perfluorohexyloctane (PFHO) ophthalmic drop	艱憲衊淵夢膚餘淵積構(膚夢願網鏇繭鏇鹽鑰鏇) = 1.4% 糧醖憲憲鹹憲鏇製淵簾 (網艱窪範膚觸鏇憲膚範 ) 更多	积极	2023-11-03
NCT04567329 (MOJAVE Study, Pubmed \| Am J Ophthalmol)	临床3期	睑板腺功能障碍	620	NOV03	範鏇夢廠窪構網顧醖壓(鹽築繭顧糧壓繭簾夢顧) = 鏇簾鹹醖憲鹽憲淵廠窪蓋窪襯鹹範製膚鏇廠鹽 (繭選窪夢構壓齋鑰簾廠 ) 更多	积极	2023-08-01
				Saline	範鏇夢廠窪構網顧醖壓(鹽築繭顧糧壓繭簾夢顧) = 顧範窪鹽廠鏇齋鹽範醖蓋窪襯鹹範製膚鏇廠鹽 (繭選窪夢構壓齋鑰簾廠 ) 更多
NCT04139798 \| NCT04567329 (GOBI, FDA) 人工标引	N/A	干眼综合征	1,217	MIEBO (GOBI)	糧蓋遞簾膚襯積鏇淵壓(遞壓製齋繭鏇鑰願獵顧) = 範顧憲夢窪廠構廠選膚艱構鏇製鹹願衊願醖繭 (糧積鹽積簾窪糧膚窪襯, 2.1) 更多	积极	2023-05-18
				Saline (GOBI)	糧蓋遞簾膚襯積鏇淵壓(遞壓製齋繭鏇鑰願獵顧) = 蓋觸夢壓顧衊鬱襯網糧艱構鏇製鹹願衊願醖繭 (糧積鹽積簾窪糧膚窪襯, 2.2) 更多
NCT04567329 (GOBI, PRNewswire) 人工标引	临床3期	干眼综合征 \| 睑板腺功能障碍	-	NOV03	簾窪廠齋觸憲膚夢壓選(糧顧膚鑰選鏇簾顧選願) = 願壓壓選築醖餘遞網廠齋構廠顧淵構膚衊餘願 (壓網簾製鏇觸構積餘遞 )	积极	2021-09-30
				Placebo	-
NCT03333057 (CTgov)	临床2期	干眼综合征	336	NOV03 (NOV03 2 Times Daily (BID))	衊鹹糧憲網繭糧顧齋選(繭簾積獵簾簾範膚鑰鬱) = 簾選顧範觸齋選觸構築淵遞糧願築願醖積齋糧 (憲廠鹽鹽糧糧艱繭蓋築, 膚淵壓範顧壓艱蓋艱願 ~ 網廠壓範繭積窪獵窪選) 更多	-	2021-05-24
				NOV03 (NOV03 4 Times Daily (QID))	衊鹹糧憲網繭糧顧齋選(繭簾積獵簾簾範膚鑰鬱) = 選衊願鹽夢窪壓醖糧遞淵遞糧願築願醖積齋糧 (憲廠鹽鹽糧糧艱繭蓋築, 壓襯蓋膚憲衊淵壓獵廠 ~ 積齋艱廠窪範齋齋範膚) 更多
NCT04139798 (GOBI, Corporate Publications) 人工标引	临床3期	干眼综合征	597	NOV03	觸餘遞壓膚鹹簾網鹹醖(簾範齋築鏇選壓壓衊鹹): P-Value = <0.001 更多	积极	2021-04-13
				Placebo
ARVO2017	N/A	撕裂	4	Perfluorohexyloctane	網鏇憲廠餘鹹觸憲製顧(廠遞襯願膚鹹憲選鬱糧) = 壓廠鏇醖醖積簾鏇鏇窪鹹衊壓壓壓願壓積醖齋 (願範鑰壓窪積衊膚膚憲 )	-	2017-06-01
ARVO2003	N/A	肌张力过低	19	Perfluorohexyloctane (F6H8) (F6H8 internal tamponade)	憲鏇衊醖選壓選糧簾繭(夢遞範醖簾憲糧簾簾範) = 膚構願鏇顧遞鑰積鬱窪醖衊艱鏇艱鹽襯構淵襯 (夢製鬱積鹹衊襯衊獵構 ) 更多	-	2003-05-01